Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2-Reference-Cited by-同舟云学术

Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2

Published:2017-02-22 Issue:378 Volume:9 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Ler Lian Dee¹²³^ORCID,Ghosh Sujoy⁴⁵^ORCID,Chai Xiaoran⁵,Thike Aye Aye⁶^ORCID,Heng Hong Lee¹²,Siew Ee Yan¹²^ORCID,Dey Sucharita⁷,Koh Liang Kai¹²^ORCID,Lim Jing Quan¹²^ORCID,Lim Weng Khong¹²^ORCID,Myint Swe Swe¹²,Loh Jia Liang¹²,Ong Pauline¹²^ORCID,Sam Xin Xiu⁶^ORCID,Huang Dachuan¹²,Lim Tony⁶,Tan Puay Hoon⁶^ORCID,Nagarajan Sanjanaa¹²,Cheng Christopher Wai Sam⁸,Ho Henry⁸,Ng Lay Guat⁸^ORCID,Yuen John⁸,Lin Po-Hung⁹^ORCID,Chuang Cheng-Keng⁹^ORCID,Chang Ying-Hsu⁹,Weng Wen-Hui¹⁰^ORCID,Rozen Steven G.²⁵^ORCID,Tan Patrick²⁷¹¹¹²,Creasy Caretha L.¹³^ORCID,Pang See-Tong⁹^ORCID,McCabe Michael T.¹³^ORCID,Poon Song Ling¹²,Teh Bin Tean¹²⁷¹⁴^ORCID

Affiliation:

1. Laboratory of Cancer Epigenome, Division of Medical Sciences, National Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610, Singapore.

2. Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, 8 College Road, Singapore 169857, Singapore.

3. NUS Graduate School for Integrative Sciences and Engineering, 28 Medical Drive, Singapore 117456, Singapore.

4. Program in Cardiovascular and Metabolic Disorders, Duke-NUS Medical School, Singapore 169857, Singapore.

5. Centre for Computational Biology, Duke-NUS Medical School, Singapore 169857, Singapore.

6. Department of Pathology, Singapore General Hospital, Singapore, Singapore.

7. Cancer Science Institute of Singapore, National University of Singapore, Centre for Life Sciences, Singapore 117456, Singapore.

8. Department of Urology, Singapore General Hospital, Outram Road, Singapore 169608, Singapore.

9. Division of Urooncology, Department of Urology, Chang Gung University and Memorial Hospital at LinKou, TaoYuan, Taiwan.

10. Department of Chemical Engineering and Biotechnology and Graduate Institute of Biochemical and Biomedical Engineering, National Taipei University of Technology, Taipei, Taiwan.

11. Division of Cellular and Molecular Research, National Cancer Centre Singapore, Singapore 169610, Singapore.

12. Genome Institute of Singapore, 60 Biopolis Street Genome, Singapore 138672, Singapore.

13. Cancer Epigenetics Discovery Performance Unit, Oncology R&D, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA 19426, USA.

14. Institute of Molecular and Cell Biology, 61 Biopolis Drive, Proteos, #07-18, Singapore 138673, Singapore.

Abstract

Bladder cancer with loss of KDM6A expression is vulnerable to inhibition of EZH2.

Funder

Singapore National Medical Research Council

Singapore National Cancer Centre Research Fund

Verdant Foundation

Duke-NUS Medical School

Cancer Science Institute, Singapore

Chang Gung Memorial Hospital

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference73 articles.

1. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

2. Urothelial tumorigenesis: a tale of divergent pathways

3. Bladder cancer

4. Urothelial carcinoma of the bladder: definition, treatment and future efforts

5. The Economics of Bladder Cancer: Costs and Considerations of Caring for This Disease

Cited by 170 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Wnt-deficient and hypoxic environment orchestrates squamous reprogramming of human pancreatic ductal adenocarcinoma;Nature Cell Biology;2024-09-04

2. The impact of mosaic loss of the Y chromosome (mLOY) in men of advanced age;Biogerontology;2024-09-02

3. Artemisinin pre-treatment fore cisplatin dosage enhances high grade urothelial carcinoma treatment in male albino mice via reverse gene expression modulation of FGFR3, HRAS, P53 and KDM6A;BMC Cancer;2024-08-08

4. CRISPR–Cas9 potential for identifying novel therapeutic targets in muscle-invasive bladder cancer;Nature Reviews Urology;2024-07-01

5. Unveiling the Molecular Landscape of Pancreatic Ductal Adenocarcinoma: Insights into the Role of the COMPASS-like Complex;International Journal of Molecular Sciences;2024-05-07